Results 121 to 130 of about 29,030 (239)

Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.

PLoS Pathogens, 2012
Progressive multifocal leukoencephalopathy (PML) induced by JC virus (JCV) is a risk for natalizumab-treated multiple sclerosis (MS) patients. Here we characterize the JCV-specific T cell responses in healthy donors and natalizumab-treated MS patients to
Molly R Perkins, Caroline Ryschkewitsch, Julia C Liebner, Maria Chiara G Monaco, Danielle Himelfarb, Sara Ireland, Annelys Roque, Heather L Edward, Peter N Jensen, Gina Remington, Thomas Abraham, Jaspreet Abraham, Benjamin Greenberg, Charles Kaufman, Chris LaGanke, Nancy L Monson, Xiaoning Xu, Elliot Frohman, Eugene O Major, Daniel C Douek   +19 more
doaj   +1 more source

Natalizumab therapy, 2013 [PDF]

, 2014
Multiple sclerosis (MS) is the most common chronic disease of the central nervous system in young adults. No curative therapy is known. Currently, six drugs are available that can reduce the activity of MS.
Bencsik, Krisztina, Karácsony, M., Vécsei, László   +2 more
core  

Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: systematic review and meta-regression

, 2013
Background: Recent studies have shown a decrease in annualised relapse rates (ARRs) in placebo groups of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS).
Friede, Tim, Nicholas, Richard, Röver, Christian, Schneider, Simon, Steinvorth, Simon M., Straube, Sebastian   +5 more
core   +1 more source

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Therapeutic Advances in Neurological Disorders, 2019
Background: Natalizumab (NTZ) is sometimes discontinued in patients with multiple sclerosis, mainly due to concerns about the risk of progressive multifocal leukoencephalopathy.
L. Prosperini, R. Kinkel, Augusto A Miravalle, P. Iaffaldano, S. Fantaccini   +4 more
semanticscholar   +1 more source

Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial [PDF]

, 2016
Introduction The efficacy of natalizumab was evaluated in Japanese patients with relapsing-remitting multiple sclerosis (RRMS) in a 24-week, phase 2 bridging study.
Deb Steiner, Geoffrey Kuesters, J. T. Tibung, Jun-Ichi Kira, Nisha Lucas, Nobuhisa Ohtsuka, null null, Shinichi Torii, Shuji Kishida, Takahiko Saida, Takashi Yamamura, Yan Ling   +11 more
core   +1 more source

Acute Intermittent Hypoxia Exerts Beneficial Effects and Promotes Repair in Male Mice in the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis

Glia, Volume 74, Issue 2, February 2026.
Acute intermittent hypoxia is a novel, noninvasive therapy that shows promising and similar beneficial repair and remyelination following demyelination in male experimental autoimmune encephalomyelitis, as was previously shown in female mice. ABSTRACT Multiple sclerosis (MS) affects women more frequently than men, but the disease progresses more ...
Nataliya Tokarska, Josh Roberts, Sameer Rathnayaka Koralage, Justin M. A. Naniong, Jayne M. Johnston, Zelan Wei, Valerie M. K. Verge   +6 more
wiley   +1 more source

When Strong Recommendations Rest on Weak Evidence: Lessons From Therapeutic Apheresis Guidelines

Journal of Clinical Apheresis, Volume 41, Issue 1, February 2026.
ABSTRACT The American Society for Apheresis (ASFA) guidelines serve as a global standard for therapeutic apheresis practice. However, our analysis of the 2023 guidelines reveals discordance between the strength of recommendation and the quality of evidence. Among 166 indications, one‐third carry strong recommendations, yet only 8% are supported by high‐
Jeremy W. Jacobs, Garrett S. Booth, Brian D. Adkins, Victoria Costa, Sheharyar Raza, Yara A. Park, Joseph Yossi Schwartz, Evan M. Bloch   +7 more
wiley   +1 more source

Natalizumab for the treatment of relapsing multiple sclerosis

Biologics: Targets & Therapy, 2008
Richard A Rudick1, Michael A Panzara21Cleveland Clinic Foundation, Cleveland, OH, USA; 2Biogen Idec, Inc., Cambridge, MA, USAAbstract: Natalizumab is an α4-integrin antagonist approved as monotherapy for patients with relapsing multiple ...
Richard A Rudick, Michael A Panzara
doaj  

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo, Hui Liu, Yu‐Jing Song, Jian‐Hua Wang, Danfeng Liu, Zhi‐Wei Zheng, Jia‐Jun Li, Boya Li, An Song, Wei He, Lei‐Lei Yang, Shuo Wang   +11 more
wiley   +1 more source

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up

Frontiers in Neurology, 2018
Natalizumab inhibits the transmigration of immune cells across the blood-brain barrier thus inhibiting inflammation in the central nervous system.
Maxi Kaufmann, Rocco Haase, Undine Proschmann, Tjalf Ziemssen, Katja Akgün   +4 more
doaj   +1 more source